Welcome to our dedicated page for Madrigal Pharmaceuticals news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmaceuticals stock.
Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 p.m. EDT. The company’s presentation will be webcast live and accessible via Madrigal’s Investor Relations Events and Presentations page, with a replay available after the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 15, 2026 to 13 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The awards total 4,676 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Reed is Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson, leading R&D across oncology, immunology, neuroscience and other serious diseases.
According to Madrigal, his extensive scientific, leadership and global drug development experience is expected to support the company as it advances Rezdiffra and its broader MASH pipeline.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 1, 2026 to ten new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 4,263 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment at each vesting date.
Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will participate in the Canaccord Genuity Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company’s presentation will be webcast live, with access via Madrigal’s Investor Relations Events and Presentations page, and a replay available after the event.
Madrigal Pharmaceuticals (Nasdaq: MDGL) reported second-quarter 2026 net revenues of $364.3 million, up 71% from $212.8 million a year earlier, driven by higher U.S. demand for Rezdiffra (resmetirom). As of June 30, 2026, more than 49,000 patients were on Rezdiffra, with the company noting it has since surpassed 50,000 active patients.
Operating expenses rose to $420.6 million (including $35.4 million stock-based compensation), leading to a net loss of $57.9 million, or $1.99 per share. Madrigal ended the quarter with $838.9 million in cash, cash equivalents, restricted cash and marketable securities. The company strengthened its Rezdiffra IP with three new U.S. patents extending into 2042–2045 and initiated dosing in a Phase 1 trial of MGL-2086, an oral GLP-1, as part of a planned Rezdiffra combination program in MASH.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on July 15, 2026 to ten new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Rule 5635(c)(4).
Awards total options for 4,770 shares at a $550.25 exercise price, plus 7,433 time-based and 1,908 performance-based RSUs, with multi‑year vesting tied to continued employment and relative total shareholder return.
Madrigal Pharmaceuticals (Nasdaq: MDGL) plans to release its second-quarter 2026 financial results on Thursday, July 30, 2026, before the U.S. market opens. Management will host a live webcast at 8:00 a.m. Eastern Time, accessible via the company’s Investor Relations website, with a replay available about two hours later.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced that the USPTO has issued three new U.S. patents covering resmetirom (Rezdiffra) across MASH populations. Two patents, Nos. 12,667,575 and 12,661,359, relate to F2/F3 MASH treatment regimens and are expected to provide protection to 2045 and 2042, respectively; both will be listed in the FDA’s Orange Book.
A third patent, No. 12,661,361, covers a method of administering resmetirom to treat well-compensated cirrhosis (F4c) and is expected to provide protection to 2042. According to Madrigal Pharmaceuticals, these grants strengthen its resmetirom IP estate in MASH and potential F4c indications.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on July 1, 2026 to seven new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee. Awards total 604 stock options and 2,952 time-based RSUs at a $514.39 exercise price, with multi-year vesting tied to continued employment.